How to maintain continuity in peptide care

When several clinicians or telehealth services are involved, identify who owns the treatment decision and who will review results. Share the diagnosis and current medicine list with the primary care team when appropriate. AHRQ recommends bringing a complete medicine list and asking questions until the plan is clear. Fragmented records can lead to duplicate therapy or a missed interaction. AHRQ: Talk with your doctor

Keep the brand or generic name, formulation, pharmacy, prescriber, start date, and any product changes. “Peptide injection” is not specific enough for a new clinician. FDA labels are product-specific, and compounded preparations are not FDA-approved versions of the named brand. If a service changes the compounder or product between refills, ask whether instructions, monitoring, or expected effects need review. FDA: Labeling FAQ for prescription medicines FDA: Compounding and the FDA Q&A

Ask how far ahead to request refills, who handles authorization, and what happens if the product is unavailable or the clinician leaves. FDA’s shortage resources show that supply status can change; a refill problem does not mean a research-use product is a suitable replacement. The plan should tell you whom to contact rather than leaving you to improvise. FDA: Compounding during drug shortages

New symptoms, pregnancy, another diagnosis, or a change in other medicines can alter the benefit-risk balance. Ask for a follow-up date and what will be measured. If you suspect a serious reaction, contact the treating team and consider a MedWatch report. Continuity means keeping the decision current, not simply receiving the next shipment. FDA: Reporting serious problems

Keep a short record with the condition, product and form, start date, reason it was chosen, response so far, adverse effects, next review date, prescriber, and pharmacy. This is especially useful when visiting urgent care or switching providers. If the product is compounded, include the compounder and lot when known. An ordinary medication list can prevent a new clinician from treating two similar names as separate unrelated products. AHRQ: Talk with your doctor

A platform may change clinicians, pharmacies, or product sourcing. Ask for notice of any material change and a chance to review it before the next fill. An approved brand and a new compounded product are not automatically interchangeable, nor are two differently labeled compounded formulations. A clinician should decide whether the original plan still fits the patient and explain any revised instructions. FDA: Compounding and the FDA Q&A

Even a stable prescription should be revisited when diagnoses, other medicines, insurance, or product labeling change. Ask whether the original goal is still being met and whether the same clinician remains responsible for monitoring. Continuity is a living record of the treatment rationale, not a standing order that can run indefinitely without reassessment. AHRQ: SHARE approach